Biotech Values

[DonShimoda]

I've had it on my watch list for awhile myself. I never pulled the trigger because I haven't had the time to do the dd on why attempts by other companies to use hypoxia as a targeting agent failed. Also, as a general rule I try to avoid pancreatic phase 2's.

I am interested in the upcoming P3 sarcoma results expected by the end of the year and may take a position closer to that time.

At least I did include the name in my charity portfolio, lol.